BioSpace News Archive

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced results of a new nationwide survey on chronic nasal congestion, its impact on daily activities, and awareness of nasal polyps as a possible cause.

2021 EPS guidance lowered to be in the range of $7.03 to $7.23 on a reported basis and adjusted to be in the range of $7.80 to $8.00 on a non-GAAP basis.

Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies

Aravive Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer.

PharmaTher Holdings Ltd., a specialty psychedelic pharmaceutical company, announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity, based on the evaluation of the Company’s drug repurposing artificial intelligence platform, panaceAI™.

Dr. Gelfman brings over twenty years of successful ophthalmic research and development experience to the Foundation executive team.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 , at 12:30 p.m. Eastern Time .

Valeo Pharma Inc . (CSE: VPH) a Canadian pharmaceutical company, announced today that it has upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units